Main Office (805) 934-0600
HCO License #424700018

Recent News

18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against 15O-H2O PET

Dual-biomarker positron emission tomography (PET), providing complementary information on cerebral blood flow and amyloid-β deposition, is of clinical interest for Alzheimer's disease (AD). The purpose of this study was to validate the perfusion components of early-phase 18F-florbetapir (eAV45), the 18F-AV45 delivery rate (R1), and 18F-FDG against 15O-H2O PET and assess how they change with disease… Read More

Traumatic brain injury and Alzheimer's disease neuropathology

Traumatic brain injury (TBI) as a risk factor for the development of late-life dementia, including Alzheimer's disease (AD), is a matter of discussion [1–4], and only a few studies examined the potential relationship between residual TBI lesions and AD neuropathology [5–9]. Examining 4761 deceased participants from the National Alzheimer's Coordination Center (NACC) of the years… Read More
Our Partners